| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
As a chemical intermediate for ADC linker synthesis, Benzyl 2-cyclopropyl-2-hydroxyacetate does not have a defined biological target. Its role is to serve as a building block in the synthesis of linkers for antibody-drug conjugates. The compound provides a cyclopropyl-containing scaffold that can be further functionalized to create linkers with specific properties. The benzyl ester group allows for selective deprotection.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, this compound is used as an intermediate in the synthesis of ADC linkers. The benzyl ester can be deprotected to reveal a carboxylic acid for further conjugation. The hydroxyl group can be functionalized for attachment to payloads such as Exatecan. The resulting linkers can be coupled to antibodies such as hu2F7.
|
| ln Vivo |
This compound does not exhibit direct cellular activity as it is a chemical intermediate rather than a bioactive molecule. ADC linkers synthesized using this intermediate can be incorporated into ADCs that are delivered to target cells where the antibody binds to cell surface antigens, followed by internalization and payload release. The cyclopropyl-containing linker may influence the physicochemical properties of the resulting ADC.
|
| Enzyme Assay |
The standard procedure for using this compound involves its use as a starting material in organic synthesis for ADC linker preparation. The benzyl ester can be removed by hydrogenolysis to yield the carboxylic acid. The hydroxyl group can be activated for conjugation to payloads such as Exatecan. The resulting linker can be coupled to antibodies. The efficiency of each synthetic step is assessed by NMR, mass spectrometry, or HPLC analysis.
|
| Cell Assay |
No cell-based experimental protocols are directly applicable to this compound as it is a chemical synthesis intermediate. ADC linkers synthesized using this intermediate can be incorporated into ADCs that are evaluated in cell culture experiments. Typical protocols include treating cancer cell lines with the ADC and assessing cell viability using MTT or CCK-8 assays.
|
| Animal Protocol |
This compound is not administered to animals as it is a chemical intermediate for ADC linker synthesis. ADCs incorporating linkers derived from this intermediate may be evaluated in animal models for pharmacokinetics and efficacy. Typical studies involve administration of the ADC to tumor-bearing mice via intravenous routes. Tumor volumes are measured, and tissues are collected for analysis.
|
| ADME/Pharmacokinetics |
As a chemical reagent, this compound does not have established pharmacokinetic properties. The compound is used as a synthetic intermediate and is not administered systemically. The compound is typically stored at -20°C. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
The compound is not intended for therapeutic use and lacks established toxicity profiles. Standard laboratory safety precautions should be observed when handling this chemical reagent. The compound is for research use only and is not for human therapeutic applications.
|
| Additional Infomation |
Benzyl 2-cyclopropyl-2-hydroxyacetate is a research-grade chemical supplied as an intermediate for ADC linker synthesis. It is not an approved pharmaceutical and has no clinical trial history. The linker consisting of this compound can be coupled to Exatecan and combined with antibodies such as antibody hu2F7. This product is intended for research use only.
|
| Exact Mass |
206.094
|
|---|---|
| CAS # |
182747-31-5
|
| PubChem CID |
67133797
|
| Appearance |
Colorless to light yellow liquid（Density：1.234±0.06 g/cm3）
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
217
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC1C(C(=O)OCC2=CC=CC=C2)O
|
| InChi Key |
HBEZCBDGJMYNGS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H14O3/c13-11(10-6-7-10)12(14)15-8-9-4-2-1-3-5-9/h1-5,10-11,13H,6-8H2
|
| Chemical Name |
benzyl 2-cyclopropyl-2-hydroxyacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
